Gilead To Acquire All Remaining Rights To Potential First-In-Class Immunotherapy GS-1811 From Jounce Therapeutics
Go back to Gilead To Acquire All Remaining Rights To Potential First-In-Class Immunotherapy GS-1811 From Jounce Therapeutics| Gilead Sciences (NASDAQ: GILD) | Delayed: 146.12 +2.68 (1.87%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $143.44 | 52 Week High | $108.63 | |||
| Open | $144.52 | 52 Week Low | $71.39 | |||
| Day High | $147.91 | P/E | 80.73 | |||
| Day Low | $143.50 | EPS | $1.81 | |||
| Volume | 5,384,399 | |||||
| (NASDAQ: JNCE) | Delayed: 1.88 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $1.88 | 52 Week High | $ | |||
| Open | $13.36 | 52 Week Low | $ | |||
| Day High | $1.88 | P/E | N/A | |||
| Day Low | $1.88 | EPS | $ | |||
| Volume | 325,016 | |||||
